{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T13:21:07Z","timestamp":1784208067716,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2006,3]]},"DOI":"10.1016\/j.bcmd.2005.12.017","type":"journal-article","created":{"date-parts":[[2006,2,16]],"date-time":"2006-02-16T07:21:15Z","timestamp":1140074475000},"page":"171-176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Aspirin \u201cresistance\u201d"],"prefix":"10.1016","volume":"36","author":[{"given":"Karsten","family":"Schr\u00f6r","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur-Aron","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hohlfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2005.12.017_bib1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/09537100120104890","article-title":"Towards a definition of aspirin resistance: a typological approach","volume":"13","author":"Weber","year":"2002","journal-title":"Platelets"},{"key":"10.1016\/j.bcmd.2005.12.017_bib2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1053\/pcad.2002.123467","article-title":"Pharmacogenomics in cardiovascular diseases","volume":"44","author":"Mukherjee","year":"2002","journal-title":"Prog. Cardiovasc. Dis."},{"key":"10.1016\/j.bcmd.2005.12.017_bib3","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1161\/01.ATV.0000145980.39477.a9","article-title":"Aspirin and clopidogrel. Efficacy, safety, and the issue of drug resistance","volume":"24","author":"Cattaneo","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.bcmd.2005.12.017_bib4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1055\/s-0037-1613290","article-title":"Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance","volume":"88","author":"McKee","year":"2002","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.bcmd.2005.12.017_bib5","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.jacc.2004.08.070","article-title":"Aspirin resistance and atherothrombotic disease","volume":"46","author":"Mason","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.bcmd.2005.12.017_bib6","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1161\/01.CIR.0000142056.69970.DB","article-title":"Terms and conditions. Semantic complexicity and aspirin resistance","volume":"110","author":"Hennekens","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.bcmd.2005.12.017_bib7","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-142-5-200503010-00012","article-title":"Narrative review: aspirin resistance and its clinical implications","volume":"142","author":"Sanderson","year":"2005","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.bcmd.2005.12.017_bib8","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1055\/s-0038-1645038","article-title":"Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina","volume":"63","author":"Vejar","year":"1990","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.bcmd.2005.12.017_bib9","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/j.1552-4604.1995.tb04044.x","article-title":"Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers","volume":"35","author":"Benedek","year":"1995","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.bcmd.2005.12.017_bib10","first-page":"221","article-title":"Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically","volume":"11","author":"Buchanan","year":"1995","journal-title":"J. Can. Cardiol."},{"key":"10.1016\/j.bcmd.2005.12.017_bib11","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1161\/01.STR.23.10.1400","article-title":"The effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin","volume":"23","author":"Tohgi","year":"1992","journal-title":"Stroke"},{"key":"10.1016\/j.bcmd.2005.12.017_bib12","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1161\/01.STR.25.12.2331","article-title":"Development of aspirin resistance in persons with previous ischemic stroke","volume":"25","author":"Helgason","year":"1994","journal-title":"Stroke"},{"key":"10.1016\/j.bcmd.2005.12.017_bib13","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1055\/s-0038-1657677","article-title":"Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty","volume":"78","author":"Mueller","year":"1997","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.bcmd.2005.12.017_bib14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"Br. J. Med."},{"key":"10.1016\/j.bcmd.2005.12.017_bib15","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1055\/s-2007-996108","article-title":"Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis","volume":"23","author":"Schr\u00f6r","year":"1997","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.bcmd.2005.12.017_bib16","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1182\/blood.V69.1.180.180","article-title":"Inhibition of thromboxane formation in vivo and ex vivo","volume":"69","author":"Reilly","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2005.12.017_bib17","first-page":"733","article-title":"The affinities of prostaglandin H2 and thromboxane A2 for their receptor are similar in washed human platelets","volume":"157","author":"Mayeux","year":"1988","journal-title":"Biochem. Biophys. Acta"},{"key":"10.1016\/j.bcmd.2005.12.017_bib18","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1046\/j.1538-7836.2003.00354.x","article-title":"Aspirin resistance: a revival of platelet aggregation tests?","volume":"1","author":"De Gaetano","year":"2003","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.bcmd.2005.12.017_bib19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrd985","article-title":"Scientific and therapeutic advances in antiplatelet therapy","volume":"2","author":"Bhatt","year":"2003","journal-title":"Nat. Rev., Drug Discov."},{"key":"10.1016\/j.bcmd.2005.12.017_bib20","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0002-9149(01)01631-9","article-title":"Profile and prevalence of aspirin resistance in patients with cardiovascular disease","volume":"88","author":"Gum","year":"2001","journal-title":"J. Am. Cardiol."},{"key":"10.1016\/j.bcmd.2005.12.017_bib21","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1161\/01.CIR.0000081770.51929.5A","article-title":"Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery","volume":"108","author":"Zimmermann","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.bcmd.2005.12.017_bib22","doi-asserted-by":"crossref","first-page":"5861","DOI":"10.1073\/pnas.83.16.5861","article-title":"11-DH-Thromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation","volume":"83","author":"Catella","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcmd.2005.12.017_bib23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0735-1097(94)90538-X","article-title":"Eicosanoid biosynthesis in patients with stable angina: beneficial effects of very low dose aspirin","volume":"24","author":"Montalescot","year":"1994","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.bcmd.2005.12.017_bib24","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1161\/01.CIR.102.9.1007","article-title":"Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina","volume":"102","author":"Cipollone","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.bcmd.2005.12.017_bib25","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1161\/01.CIR.0000013777.21160.07","article-title":"Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke or cardiovascular death in patients at high risk for cardiovascular events","volume":"105","author":"Eikelboom","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.bcmd.2005.12.017_bib26","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.amjcard.2004.12.038","article-title":"Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction","volume":"95","author":"Schwartz","year":"2005","journal-title":"J. Am. Cardiol."},{"key":"10.1016\/j.bcmd.2005.12.017_bib27","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa003199","article-title":"Cyclooxygenase inhibitors and the antiplatelet effect of aspirin","volume":"345","author":"Catella-Lawson","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2005.12.017_bib28","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1161\/01.ATV.3.4.383","article-title":"Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin","volume":"3","author":"Rao","year":"1983","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.bcmd.2005.12.017_bib29","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S0140-6736(03)12560-3","article-title":"Parsing an enigma: the pharmacodynamics of aspirin resistance","volume":"361","author":"FitzGerald","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2005.12.017_bib30","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/S0140-6736(99)00498-5","article-title":"Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance","volume":"353","author":"Weber","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2005.12.017_bib31","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1160\/TH04-05-0302","article-title":"Cyclooxygenase COX-2a, a novel COX-2 mRNA variant, in platelets from patients after coronary artery bypass grafting","volume":"92","author":"Censarek","year":"2004","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.bcmd.2005.12.017_bib32","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1136\/bmj.327.7427.1309","article-title":"Indirect comparison meta-analysis of aspirin therapy after coronary surgery","volume":"327","author":"Lim","year":"2003","journal-title":"Br. J. Med"},{"key":"10.1016\/j.bcmd.2005.12.017_bib33","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.amjmed.2005.03.041","article-title":"Low-dose aspirin increases aspirin resistance in patients with coronary artery disease","volume":"118","author":"Lee","year":"2005","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bcmd.2005.12.017_bib34","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1161\/01.CIR.101.24.2833","article-title":"Cardiovascular responses to the isoprostanes iPF (2\u03b1)-III and iPE (2)-III are mediated via the thromboxane A (2) receptor in vivo","volume":"101","author":"Audoly","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.bcmd.2005.12.017_bib35","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.2337\/diabetes.53.4.1046","article-title":"Diabetic patients without vascular complications display enhanced basal platelet activation and decreased antioxidant status","volume":"53","author":"Vericel","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.bcmd.2005.12.017_bib36","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1023\/A:1022066305399","article-title":"Aspirin resistance and genetic polymorphism","volume":"14","author":"Cambria-Kiely","year":"2002","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.bcmd.2005.12.017_bib37","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1067\/mcp.2003.1","article-title":"Genetic variation in cyclooxygenase 1: effects on response to aspirin","volume":"73","author":"Halushka","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcmd.2005.12.017_bib38","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.jacc.2003.12.034","article-title":"Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment","volume":"43","author":"Chen","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.bcmd.2005.12.017_bib39","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0735-1097(02)03014-0","article-title":"A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease","volume":"41","author":"Gum","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.bcmd.2005.12.017_bib40","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1016\/j.amjcard.2003.08.072","article-title":"Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA","volume":"92","author":"Wang","year":"2003","journal-title":"J. Am. Cardiol."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979606000192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979606000192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:23:12Z","timestamp":1761049392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979606000192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["S1079979606000192"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2005.12.017","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2006,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aspirin \u201cresistance\u201d","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2005.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}